Apellis Pharmaceuticals Announces Royalty Buy-Down Agreement with Sobi

Details

entered into a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi). Under this agreement, Sobi will pay Apellis an upfront payment of $275 million and up to an additional $25 million upon EMA approval of Aspaveli for certain indications. In return, Apellis will reduce Sobi's royalty payment obligations by 90%, subject to performance-based caps. The agreement also includes terms regarding the extension of certain prepayment premiums under Apellis's financing agreement with Sixth Street Lending Partners.

Items reported

About Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.